AstraZeneca developing reversal agent for heart drug Brilinta

November 13, 2014 11:11 AM

12 0

LONDON (Reuters) - AstraZeneca is developing an antibody treatment to reverse the blood-thinning effect of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event of major bleeding.

The move could give Brilinta an edge among drugs that block platelets in the blood, since there are no approved products to counteract their effects. Because they reduce clotting, the drugs can cause problems if doctors need to operate suddenly.

Read more

To category page